AorTech International PLC Directors' Disclosures (6780C)
19 June 2019 - 4:00PM
UK Regulatory
TIDMAOR
RNS Number : 6780C
AorTech International PLC
19 June 2019
AorTech International plc
("AorTech", the "Company" or the "Group")
Directors' Disclosures
AorTech International plc (AIM: AOR.L), the licensor of the
world's leading long-term implantable biostable polymer
(Elast-Eon(TM) ) and developer of medical devices utilising the key
properties of Elast-Eon(TM) , makes the following disclosures
pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules
for Companies in relation to Geoffrey Alan Berg (aged 63), David
Muir Richmond (aged 56) and John Louis Ely (aged 68).
Mr Berg, on appointment as Non-Executive Director of AorTech,
was a director of Berg Medical Limited and, during the five years
prior to his appointment, had been a director of the Scottish
Cardiac Society.
Mr Richmond, on appointment as Non-Executive Director of AorTech
was a director of the following companies:
Blue Opal Resourcing Limited
Braidlock Limited
Culzean Medical Devices Limited
Rua Medical Devices Limited
On appointment, Mr Berg held 16,667 ordinary shares in AorTech
("Shares"), representing 0.11 per cent of the issued share capital
of the Company. His holding remains the same today.
On appointment, Mr Richmond held 33,334 Shares, representing
0.23 per cent of the issued share capital of the Company. His
holding remains the same today.
On appointment, Mr Ely held no ordinary shares in AorTech. His
holding remains the same today.
This information was in error not included in the Company's
announcement on 20 July 2018 relating to, inter alia, the
appointments of Mr Berg, Mr Richmond and Mr Ely.
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Chairman
Stockdale Securities Limited Tel: +44 (0)20 7601 6100
Tom Griffiths/David Coaten
About AorTech:
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM) the world's leading long-term
implantable co-polymers, now manufactured on their behalf by
Biomerics LLC in Utah, USA. With several million implants and seven
years of successful clinical use, AorTech polymers are being
developed and used in cardiology and urological applications,
including pacing leads, cardiac cannulae, stents and neuro
stimulation devices. Devices manufactured from AorTech polymers
have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA
and Japanese Ministry of Health approvals.
Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to
silicone while exhibiting excellent mechanical, blood contacting
and flex-fatigue properties. These polymers can be processed using
conventional thermoplastic extrusion and moulding techniques. A
range of materials in a variety of application-specific
formulations for use in medical devices and components are
available.
In addition to the licensing of biostable polymers, AorTech is
now developing medical devices utilising the key properties of its
world class polymers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RDNEAKKPFSXNEFF
(END) Dow Jones Newswires
June 19, 2019 02:00 ET (06:00 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2024 to May 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From May 2023 to May 2024